If a patient presents with these findings after injecting what they believe is AOD-9604, product contamination or mislabeling should be suspected, and the vial should be retained for third-party analytical testing [10]
Fine-dispersed - the henna dissolves to the necessary consistency in seconds
GLOW Peptide Regulatory Status As of June 2026, none of the three GLOW compounds (BPC-157, TB-500, GHK-Cu) are FDA-approved for injectable human use
Many researchers who plan to escalate beyond 4mg switch to a new vial with 1mL reconstitution at that point rather than splitting draws
When available, COA or testing documents should be reviewed before laboratory use to confirm identity, lot details, and analytical information relevant to your research workflow
For others, it takes a day or two